In a move expected to increase competition and lower drug prices, the Food and Drug Administration today approved the first “biosimilar” drug, designed to closely mimic existing drugs grown in living cells.
Pharmaceutical companies have been able to produce low-cost generic drugs for three decades, but they haven’t before been able to produce knockoff versions of these more complicated therapies… Read More